Payment overview · 2025
General Payments
$464.78
21 reported records · 9 companies
Healthcare provider profile · identity verified
William Kyle Vincent, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TEMECULA, CA · NPI 1609296813
Verified facts
What the public records show
CMS Open Payments records show William Kyle Vincent, M.D. received $464.78 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $189.35 | 40.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $121.53 | 26.1% | 7 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $28.15 | 6.1% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $26.52 | 5.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.22 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.91 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.18 | 4.1% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $19.13 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.79 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $464.78 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $144.72 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.53 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.53 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $99.74 | 3 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $26.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 102 |
| Losartan Potassium | Losartan Potassium | 269 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 73 |
| Lisinopril | Lisinopril | 247 | 78 |
| Montelukast Sodium | Montelukast Sodium | 209 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 52 |
| Tramadol Hcl | Tramadol Hcl | 132 | 52 |
| Metformin Hcl | Metformin Hcl | 125 | 40 |
| Ozempic | Semaglutide | 124 | 26 |
| Trazodone Hcl | Trazodone Hcl | 113 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 31 |
| Omeprazole | Omeprazole | 100 | 41 |
| Alprazolam | Alprazolam | 89 | 25 |
| Simvastatin | Simvastatin | 84 | 27 |
| Furosemide | Furosemide | 82 | 38 |
| Gabapentin | Gabapentin | 77 | 26 |
| Baclofen | Baclofen | 76 | 37 |
| Lorazepam | Lorazepam | 70 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 24 |
| Azithromycin | Azithromycin | 65 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 14 |
| Benazepril Hcl | Benazepril Hcl | 57 | 20 |
| Alendronate Sodium | Alendronate Sodium | 56 | 12 |
| Carvedilol | Carvedilol | 55 | 17 |
| Allopurinol | Allopurinol | 53 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 14 |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Eliquis | Apixaban | 47 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 21 |
| Ibuprofen | Ibuprofen | 46 | 22 |
| Methylprednisolone | Methylprednisolone | 46 | 41 |
| Atenolol | Atenolol | 45 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 17 |
| Finasteride | Finasteride | 42 | 14 |
| Prednisone | Prednisone | 40 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 14 |
| Diazepam | Diazepam | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 33 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Famotidine | Famotidine | 32 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | 13 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Cephalexin | Cephalexin | 25 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | 11 |
| Methimazole | Methimazole | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $464.78 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, Miro3D, NEFFY, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error